Pneumococcal 20-valent conjugate (Pneu-C-20) · Pneumococcal
Health Canada DIN 02527049. Check the product and formulation on your record before using a schedule.
Plan doses for this product →Prevnar 20 is a vaccine that helps protect against serious infections caused by a common type of bacteria called pneumococcus.
PREVNAR 20 is listed under Health Canada DIN 02527049. The product record and monograph below describe this formulation; the dose schedule comes from the Canadian Immunization Guide.
02527049Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with a healthcare professional.
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
A listed product may not be stocked or publicly funded.
These steps come from the Canadian Immunization Guide's administration practices and acute reactions guidance.
The details below are adapted from a Pharmasist patient handout linked to the same product monograph. The current Canadian Immunization Guide determines the dose schedules shown later.
The practical points are adapted from the Pharmasist reference for PREVNAR 20 and its matching product monograph.
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination. Public health recommendations may differ from a product monograph's authorized schedule.
Two doses at 2 and 4 months plus a booster at 12 months.
Routine schedule for healthy infants in provinces using a 2 + 1 series, including Ontario: doses at 2 and 4 months, then a booster at 12 months of age. Minimum 8 weeks between doses; the booster is not given before 12 months of age. Infants with risk factors need the four-dose (3 + 1) schedule.
Three doses at 2, 4 and 6 months plus a booster at 12 to 15 months.
For infants with immunocompromising conditions, chronic heart, lung, kidney or liver disease, cochlear implants, CSF leak, sickle cell disease or asplenia, and premature infants: doses at 2, 4 and 6 months followed by a booster at 12 to 15 months. Minimum 8 weeks between doses; the booster is not given before 12 months of age.
One dose of Pneu-C-20 or Pneu-C-21 for all adults 65 years and older.
All adults 65 years and older: one dose of Pneu-C-20 or Pneu-C-21 regardless of earlier pneumococcal vaccination, given at least 1 year after any previous Pneu-C-13, Pneu-C-15 or Pneu-P-23 dose (8 weeks in some circumstances). No further doses are currently recommended.
One dose of Pneu-C-20 or Pneu-C-21 for adults 18 to 64 with a condition that raises the risk of pneumococcal disease.
Adults 18 to 64 with immunocompromising conditions (HIV, asplenia, transplant, cancer, immunosuppressive therapy) or other risk factors for invasive pneumococcal disease (chronic heart, lung, kidney or liver disease, diabetes, alcohol use disorder, cochlear implant, CSF leak): one dose at least 8 weeks after any earlier pneumococcal vaccine. Stem-cell transplant recipients need a three-dose series plus booster instead.
Family guidance on pregnancy: Recommended for people at high risk of pneumococcal disease.
Family guidance on breastfeeding: Recommended for people at high risk of pneumococcal disease.
This guidance applies to the vaccine family. Confirm this product's details in the monograph and with your clinician. Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026.
General information only. A suggested date is not an appointment or a prescription; a healthcare professional confirms what you need. Clinical rules reviewed on 2026-09-27.
Explore care options